Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

hypertension - strategy - diabetic patients  

hypertension - strategy - all type of patients  


Related trials

Cardio-Sis, 2009 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ACCORD blood pressure, 2008 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

REIN-2, 2005 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

AASK, 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

Toto, 1995 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

HOT, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

MDRD, 1994 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie



See also:

  • All hypertension clinical trials
  • All clinical trials of strategy
  • All clinical trials of more intensive blood pressure lowering strategie
    		•  

    ABCD (N) study, 2002

    Treatments

    Studied treatment intensive treatment (diastolic blood pressure decrease of 10 mmHg below baseline DBP)
    Control treatment moderate treatment (diastolic blood pressure goal of 80-89 mmHg)
    Remarks patients randomized to intensive therapy received either nisoldipine or enalapril in a blinded manner as the initial antihypertensive medication
    Treatments description
    Achieved systolic blood 128/137 
    Achieved diastolic blood pressure 75/81 

    Patients

    Patients diabetes patients with diastolic blood pressure between 80 and 89mmHg

    Method and design

    Randomized effectives 237 / 243 (studied vs. control)
    Design Parallel groups
    Blinding open


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Cardiovascular death

    13 / 237
         9 / 243
         classic 1,48 [0,65;3,40]

    myocardial infarction (fatal and non fatal)

    19 / 237
         15 / 243
         classic 1,30 [0,68;2,50]

    Heart failure

    12 / 237
         11 / 243
         classic 1,12 [0,50;2,49]

    All cause death

    18 / 237
         20 / 243
         0,92 [0,50;1,70]

    non cardiovascular death

    5 / 237
         11 / 243
         0,47 [0,16;1,32]

    stroke (fatal and non fatal)

    4 / 237
         13 / 243
         0,32 [0,10;0,95]

    Major cardiovascular events

    37 / 237
         39 / 243
         0,97 [0,64;1,47]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Cardiovascular death 13 / 237 (5,5%) 9 / 243 (3,7%) 1,48 [0,65;3,40]   11040 
    myocardial infarction (fatal and non fatal) 19 / 237 (8,0%) 15 / 243 (6,2%) 1,30 [0,68;2,50]   11040 
    stroke (fatal and non fatal) 4 / 237 (1,7%) 13 / 243 (5,3%) 0,32 [0,10;0,95]   11040 
    Major cardiovascular events 37 / 237 (15,6%) 39 / 243 (16,0%) 0,97 [0,64;1,47]   11040 
    All cause death 18 / 237 (7,6%) 20 / 243 (8,2%) 0,92 [0,50;1,70]   11040 
    non cardiovascular death 5 / 237 (2,1%) 11 / 243 (4,5%) 0,47 [0,16;1,32]   11040 
    Heart failure 12 / 237 (5,1%) 11 / 243 (4,5%) 1,12 [0,50;2,49]   11040 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11040: Arguedas JA, Perez MI, Wright JMTreatment blood pressure targets for hypertension.Cochrane Database Syst Rev 2009;:CD004349

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Cardiovascular death 5,49% 3,70% 1,8%
    myocardial infarction (fatal and non fatal) 8,02% 6,17% 1,8%
    stroke (fatal and non fatal) 1,69% 5,35% -36,6‰
    Major cardiovascular events 15,61% 16,05% -4,4‰
    All cause death 7,59% 8,23% -6,4‰
    non cardiovascular death 2,11% 4,53% -24,2‰
    Heart failure 5,06% 4,53% 5,4‰


    Reference(s)

    Trials register # NA
    • Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.. Kidney Int 2002;61:1086-97
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend